Twigman,
CPn10 does not now really depend on trial results. The paper on RAMPs, DAMPs and PAMPs is a game changer for Invion, and not yet appreciated by the market. This molecule, which Invion owns, is the key to all auto-immune diseases and much more. It is a new class of treatment with huge potential. The industry gets it, and we will see some action in the near future. It would take at least five years for anyone to develop one of the other RAMPs identified to the place CPn10 now is, and there is a high likelihood of failure along the way.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
13.0¢ |
Change
0.005(4.00%) |
Mkt cap ! $11.01M | |||
| Open | High | Low | Value | Volume |
| 12.5¢ | 13.5¢ | 12.5¢ | $36.56K | 283.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 247400 | 12.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 13.0¢ | 119856 | 1 |
View Market Depth
| Last trade - 15.40pm 23/06/2025 (20 minute delay) ? |
| IVX (ASX) Chart |